Related Experiment Video
Updated: Jul 9, 2025

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
[Recent advances in the development of vaccines against hemorrhagic fevers caused by arenaviruses]
Mathieu Mateo1, Sylvain Baize1
1Institut Pasteur, Université Paris Cité, Unité de biologie des infections virales émergentes, Paris, France - Centre international de recherche en infectiologie (CIRI), université de Lyon, Inserm U1111, école normale supérieure de Lyon, université Lyon 1, CNRS UMR5308, 69-007, Lyon, France.
Abstract:
Arenaviruses are a global threat, causing thousands of deaths each year in several countries around the world. Despite strong efforts in the development of vaccine candidates, vaccines against Lassa fever or Bolivian and Venezuelan hemorrhagic fevers are yet to be licensed for a use in humans. In this synthesis, we present the arenaviruses causing fatal diseases in humans and the main vaccine candidates that have been developed over the past decades with an emphasis on the measles-Lassa vaccine, the first Lassa vaccine ever tested in humans, and on the MOPEVAC platform that can potentially be used as a pan-arenavirus vaccine platform.

